Objective: Well-differentiated villoglandular adenocarcinoma (VGA) of the cervix involves papillae lined by different types of epithelial cells that are histologically subclassified into endocervical, endometrioid, or intestinal subtypes. The objective of the current study was to evaluate the definite cytological features of VGA by histological subtype. Study Design: We examined 8 cervical smears from patients confirmed to have pure VGA and classified them into the 3 histological subtypes. Results: The cervical smears were highly cellular and had a relatively clean background. The nuclei had minimal anisonucleosis and fine granular chromatin with almost inconspicuous nucleoli. The characteristic findings of the endocervical type were a palisading arrangement consisting of columnar or spindle-shaped cells with apical or elongated nuclei. Small but clear nucleoli were identified only in the endocervical type. In the endometrioid type, tumor cells consisted of cohesive sheets with smooth edges and very round nuclei. Cytoplasmic vacuolation was never observed in the endometrioid type. The tumor cells in the intestinal type were prominent with abundant cytoplasmic mucin. Conclusions: We demonstrated that the cytological features of this tumor can vary depending on the histological subtype and one should be aware of these features in order to improve diagnostic accuracy.

Young RH, Scully RE: Villoglandular papillary adenocarcinoma of the uterine cervix. A clinicopathologic analysis of 13 cases. Cancer 1989;63:1773–1779.
Kaku T, Kamura T, Shigematsu T, Sakai K, Nakanami N, Uehira K, Amada S, Kobayashi H, Saito T, Nakano H: Adenocarcinoma of the uterine cervix with predominantly villoglandular papillary growth pattern. Gynecol Oncol 1997;64:147–152.
Utsugi K, Shimizu Y, Akiyama F, Umezawa S, Hasumi K: Clinicopathologic features of villoglandular papillary adenocarcinoma of the uterine cervix. Gynecol Oncol 2004;92:64–70.
Kurman RJ, Ronnett BM, Sherman ME, Wilkinson EJ: Tumours of the cervix, vagina and vulva; in Atlas of Tumor Pathology. 4th Series. Washington, American Registry of Pathology, 2010, pp 179–185.
Jones MW, Silverberg SG, Kurman RJ: Well-differentiated villoglandular adenocarcinoma of the uterine cervix: a clinicopathological study of 24 cases. Int J Gynecol Pathol 1993;12:1–7.
Kurman RJ: Carcinoma and other tumors of the cervix; in Blaunstein’s Pathology of the Female Genital Tract, ed 5. New York, Springer, 2002, pp 360–361.
Ballo MS, Silverberg SG, Sidawy MK: Cytologic features of well-differentiated villoglandular adenocarcinoma of the cervix. Acta Cytol 1996;40:536–540.
Khunamornpong S, Siriaunkgul S, Suprasert P: Well-differentiated villoglandular adenocarcinoma of the uterine cervix: cytomorphologic observation of five cases. Diagn Cytopathol 2002;26:10–14.
Chang WC, Matisic JP, Zhou C, Thomson T, Clement PB, Hayes MM: Cytologic features of villoglandular adenocarcinoma of the uterine cervix: comparison with typical endocervical adenocarcinoma with a villoglandular component and papillary serous carcinoma. Cancer 1999;87:5–11.
Novotny DB, Ferlisi P: Villoglandular adenocarcinoma of the cervix: cytologic presentation. Diagn Cytopathol 1997;17:383–387.
Ajit D, Dighe S, Gujral S: Cytologic features of villoglandular adenocarcinoma of the cervix. Acta Cytol 2004;48:288–289.
Renshaw AA, Mody DR, Lozano RL, Volk EE, Walsh MK, Davey DD, Birdsong GG: Detection of adenocarcinoma in situ of the cervix in Papanicolaou tests: comparison of diagnostic accuracy with other high-grade lesions. Arch Pathol Lab Med 2004;128:153–157.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.